Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK.
Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Br J Haematol. 2021 Jan;192(1):50-61. doi: 10.1111/bjh.16914. Epub 2020 Jul 1.
Despite considerable progress in the treatment of patients with lymphoid malignancies in recent decades, the prognosis of patients with relapsed or refractory lymphomas often remains disappointing. Increasing evidence has established the relevance of epigenetic alterations in the pathogenesis of lymphoid malignancies, and a succession of agents has been evaluated in clinical studies with varying efficacy. In the present review, we outline the importance of epigenetic modifications in lymphoma biology and discuss the published experience with epigenetic modifying agents by lymphoma subtype before considering ongoing clinical studies in this area.
尽管在过去几十年中，淋巴恶性肿瘤患者的治疗取得了相当大的进展，但复发或难治性淋巴瘤患者的预后往往仍不令人满意。越来越多的证据已经确定了表观遗传改变在淋巴恶性肿瘤发病机制中的相关性，并且已经有一系列药物在具有不同疗效的临床研究中进行了评估。在本综述中，我们概述了表观遗传修饰在淋巴瘤生物学中的重要性，并讨论了按淋巴瘤亚型分类的已发表的关于表观遗传修饰剂的经验，然后考虑了该领域正在进行的临床研究。
